Navigation Links
Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products

ST. LOUIS, Jan. 28 /PRNewswire-FirstCall/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is issuing, as previously disclosed by KV Pharmaceutical Company on January 26, 2009, a voluntary nationwide recall of the products identified below (all lots within expiration) as a precautionary measure because they may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practices (cGMPs).

One of the products, Gynazole-1, was also distributed internationally to Eastern Europe, South America, Asia, and Canada.

Patients who may have these medicines in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medication may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

    Products Recalled to WHOLESALE Level:

    Gynazole-1(R), NDC 64011-0001-08
    Clindesse(R), NDC 64011-0124-08
    microK(R) Extencaps(R) 8mEq 100, NDC 64011-0010-04
    microK(R) Extencaps(R) 8mEq UD, NDC 64011-0010-11
    microK(R) Extencaps(R) 8mEq 500, NDC 64011-0010-08
    microK(R) Extencaps(R) 10mEq 100, NDC 64011-0009-04
    microK(R) Extencaps(R) 10mEq UD, NDC 64011-0009-11
    microK(R) Extencaps(R) 10mEq 500, NDC 64011-0009-08

Any customer inquiries related to this action should be addressed to Ther-Rx Customer Service at (877) 567-7676, or faxed to Ther-Rx Customer Service at (314) 646-3701, or e-mailed to Representatives are available Monday through Friday, 8 am to 5 pm CST.

Ther-Rx Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products with instructions for returning the recalled products. Patients with questions about the recall should call the telephone number above, or contact their health care providers.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the company is unable to determine when distribution of these products will resume.

Any adverse reactions experienced with the use of these products should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at

The recall announcement is posted on

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.

SOURCE KV Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
2. Environmental Tectonics Corporation Announces the Sale of Two BARA-MED(R) XD Monoplace Hyperbaric Chambers
3. Sigma-Aldrich Corporations 4th Quarter 2008 Earnings Conference Call
4. CEL-SCI Corporation Announces 2008 Financial Results
5. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
6. Mach One Corporation Enters Letter of Intent
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
9. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
10. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
11. Met-Pro Corporation Declares Quarterly Dividend
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):